scholarly journals Metastatic Ovarian Cancer Presenting as Inflammatory Breast Cancer: A Case Report

2020 ◽  
Vol 13 (2) ◽  
pp. 867-874
Author(s):  
Mohammad Abu-Tineh ◽  
Hind Elmalik ◽  
Mohamed A. Yassin
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer ◽  
Poor Prognosis ◽  
Clear Cell ◽  
Rare Presentation ◽  
Breast Masses ◽  
Low Threshold ◽  
Shed Light

Metastatic ovarian cancer to the breast is a rare presentation, with limited cases reported worldwide. Common sites for distant metastasis in ovarian cancer are to the liver, lung, and pleura [Dauplat et al. Cancer. 1987 Oct 1;60(7):1561–6]. Usually, such cases predict poor prognosis with troublesome management. We present one challenging case of a 54-year-old female patient with recurrent clear cell ovarian cancer, presenting with right breast mass of primary versus secondary origin, progressing into inflammatory breast cancer picture. Our report aims to shed light on the value of early suspicion and low threshold of detecting secondary breast masses of ovarian cancer origin.

scholarly journals Ovarian Cancer Metastatic to the Breast Presenting as Inflammatory Breast Cancer: A Case Report and Literature Review

2010 ◽  
pp. 27-31 ◽  
Author(s):  
Rebecca L. Klein ◽  
Amanda R. Brown ◽  
Christian M. Gomez-Castro ◽  
Setsuko K. Chambers ◽  
Janiel M. Cragun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Case Report ◽  
Literature Review ◽  
Inflammatory Breast Cancer

scholarly journals Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature

2021 ◽  
pp. 1071-1079
Author(s):  
Jennifer Y. Ge ◽  
Beth Overmoyer
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer ◽  
Targeted Therapies ◽  
De Novo ◽  
Review Of The Literature ◽  
Her2 Positive ◽  
Rare Type ◽  
Favorable Prognosis ◽  
Poor Outcomes

Inflammatory breast cancer (IBC) is a rare type of breast cancer that is associated with poor outcomes compared with non-IBC. Overexpression of HER2 is enriched in IBC, and those with HER2-positive disease have a relatively favorable prognosis, with improved survival over the last two decades driven by the advent of novel targeted therapies. Here, we present two patients who have survived for over 10 years after being diagnosed with de novo metastatic HER2-positive IBC. We review the data for the treatments available for metastatic HER2-positive IBC and the evolving treatment recommendations for this disease.

Case report of bilateral inflammatory breast cancer

2009 ◽  
Vol 19 (4) ◽  
pp. 558-560 ◽  
Author(s):  
Y.A. MASANNAT ◽  
M. PETER ◽  
P. TURTON ◽  
A.M. SHAABAN
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer

Inflammatory breast cancer. A challenging disease with poor prognosis

The Breast ◽  
2018 ◽  
Vol 41 ◽  
pp. S22
Author(s):  
Mariam Salim ◽  
Hafsa Arif ◽  
Osama Shakeel ◽  
Amina Iqbal ◽  
Huma Majeed ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Poor Prognosis

scholarly journals Advanced Tracheal Adenoid Cystic Carcinoma with Thyroid Invasion Mimicking Thyroid Cancer Treated with Definitive Radiation: Case Report and Review of the Literature

2017 ◽  
Vol 10 (2) ◽  
pp. 706-712 ◽  
Author(s):  
Sondos Al Khatib ◽  
Wafa Asha ◽  
Omar Khzouz ◽  
Farid Barakat ◽  
Jamal Khader
Keyword(s):  
Breast Cancer ◽  
Thyroid Cancer ◽  
Case Report ◽  
Adenoid Cystic Carcinoma ◽  
Breast Cancer Survivor ◽  
Literature Search ◽  
Neck Swelling ◽  
Review Of The Literature ◽  
Rare Presentation ◽  
Adenoid Cystic

A 54-year-old female patient, a breast cancer survivor and a case of unresectable adenoid cystic carcinoma of the trachea, with thyroid invasion, presented with suprasternal neck swelling mimicking thyroid primary. A literature search was undertaken to highlight this rare presentation. There have been few reports in the literature describing tracheal adenoid cystic carcinoma involving the thyroid.

scholarly journals Targeting Signaling Pathways in Inflammatory Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2479
Author(s):  
Xiaoping Wang ◽  
Takashi Semba ◽  
Lan Thi Hanh Phi ◽  
Sudpreeda Chainitikun ◽  
Toshiaki Iwase ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Signaling Pathways ◽  
Inflammatory Breast Cancer ◽  
Poor Prognosis ◽  
High Rate ◽  
Novel Therapies ◽  
Biological Functions ◽  
Novel Targets ◽  
Preclinical And Clinical Studies ◽  
Related Mortality

Inflammatory breast cancer (IBC), although rare, is the most aggressive type of breast cancer. Only 2–4% of breast cancer cases are classified as IBC, but—owing to its high rate of metastasis and poor prognosis—8% to 10% of breast cancer-related mortality occur in patients with IBC. Currently, IBC-specific targeted therapies are not available, and there is a critical need for novel therapies derived via understanding novel targets. In this review, we summarize the biological functions of critical signaling pathways in the progression of IBC and the preclinical and clinical studies of targeting these pathways in IBC. We also discuss studies of crosstalk between several signaling pathways and the IBC tumor microenvironment.

Relapsed, poor-prognosis ovarian cancer, individualized, interdisciplinary treatment approach, and quality of life: a case report

2002 ◽  
Vol 10 (1) ◽  
pp. 81-83 ◽  
Author(s):  
Catharina C. Wenzel ◽  
Manuela P. Schmidinger ◽  
Gottfried J. Locker ◽  
Raimund Jakesz ◽  
Guenther G. Steger
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Case Report ◽  
Poor Prognosis ◽  
Treatment Approach ◽  
Interdisciplinary Treatment

Factors influencing survival in inflammatory breast cancer.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 136-136
Author(s):  
Julie A. Cupp ◽  
Diane Liu ◽  
Yu Shen ◽  
Naoto T. Ueno ◽  
Ricardo H. Alvarez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Poor Prognosis ◽  
Cox Model ◽  
Univariate Analysis ◽  
Progression Free Survival ◽  
Rank Test ◽  
Rapid Progression ◽  
Progression Of Disease ◽  
Delay In Treatment

136 Background: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer associated with poor prognosis, characterized by rapidly growing mass, skin changes, and regional adenopathy. The objective of this study was to determine if delay in treatment influenced survival in IBC patients. Methods: A prospective IBC database identified 93 women with stage III IBC who received care at MD Anderson from 2007 - 2012 and were retrospectively reviewed. All patients received neoadjuvant chemotherapy followed by surgery, unless progression of disease was noted, and postmastectomy radiation. Impact of time from onset of symptoms to chemotherapy or to surgery on overall survival (OS) and progression free survival (PFS) were evaluated after adjusting for the baseline covariates in the Cox model. Results: A majority of patients were white (77.4%) with an average age of 54 years. Average days from onset of symptoms to first chemo is 95 (range 16 – 387) and to surgery is 283 (range 184 – 585). Four patients had progression while on chemo. There were 14 deaths with median follow up of 2.6 years from diagnosis. In univariate analysis, delay in treatment, > 90 days from onset of symptoms to chemo, did not affect OS or PFS. Obtaining negative margins was statistically significant for OS and PFS measured from first chemo (p=0.005 and p=0.007). Positive HER-2 status was associated with longer PFS time from chemo (p=0.02, log-rank test) and from surgery (p=0.009). Positive progesterone receptor (PR) was found to be statistically significantly associated with longer OS time from chemo (p=0.01) and from surgery (p=0.03). Clinical and imaging response to chemo were associated with better OS (p=0.007 and p=0.005) and pathologic response was marginally associated with improved OS and PFS (p=0.07 and p=0.06), both measured from surgery. In multivariate Cox model, adjusting for PR or HER2, days from onset of symptoms to chemo or surgery did not have significant impact on OS or PFS. Conclusions: While traditionally delay diagnosis and treatment is considered one of the factors associated with poor prognosis, our study suggests otherwise. However, due to such rapid progression of disease, early diagnosis is still important in the overall management of patients diagnosed with IBC.

Sign in / Sign up

Export Citation Format

Share Document